[1] WHO Director-General's opening remarks at the media briefing on COVID-19 - 09 July 2020. (2020-07-09) [2020-07-10]. https://www.who.int/docs/default-source/coronaviruse/situation-reports /20200709-covid-19-sitrep-171.pdf?sfvrsn=9aba7ec7_2. [2] Xu Z,Shi L,Wang YJ,et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome.Lancet Resp Med,2020. [3] 方三高,魏建国.新型冠状病毒肺炎临床病理研究进展.重庆医学. http://kns.cnki.net/kcms/detail/50.1097.R.20200325.1157.002.html. [4] 国家卫生健康委.国家卫生健康委关于印发新型冠状病毒肺炎诊疗方案(试行第七版). (2020-03-03)[2020-04-01] http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm. [5] 李光明,潘昕.28例亳州市新型冠状病毒肺炎患者肝损伤的特征分析.临床肝胆病杂志, 2020,36(04):772-774. [6] 关贵文,高林,王建文,等.新型冠状病毒感染肺炎患者肝酶异常的机制研究.中华肝脏病杂志,2020,28(2):100-106. [7] 胡利琳,王炜珺,朱清静,等.新型冠状病毒感染肺炎相关肝损伤:病因分析及治疗策略.中华肝脏病杂志,2020,28(2)97-99. [8] Guan Wj,Ni Zy,Hu Y,et al.Clinical characte ristics of corona virus disease 2019 in China.N Engl J Med,2020.[Epub ahead of print] [9] 李丹,龙云铸,黄彭,郭文龙,吴双华,周青,傅京力.株洲地区80例新型冠状病毒肺炎患者临床特征分析.中国感染控制杂志. http://kns.cnki.net/kcms/detail/43.1390.R.20200324.1537.004.html [10] 陈凯,苏彬,杨易,王振国.新型冠状病毒肺炎病原学及临床特点研究进展.武警医学. https://doi.org/10.14010/j.cnki.wjyx.20200323.001 [11] Hoffmann M,Kleine-Weber H,Krüger N,et al.The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells.BioRxiv,2020.http://doi.org/10.1101/2020.01.31.929042. [12] Chai XQ,Hu LF,Zhang Y,et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection.2020,doi:http://dx.doi.org/10.1101/2020.02.03.931766. [13] Waseem N,Chen PH. Hypoxic hepatitis:A review and clinical update. J Clin Transl Hepatol,2016,4(3):263-268. |